AIM ImmunoTech Releases CEO Corner Segment, Discusses Recent Progress with Ampligen
ByAinvest
Thursday, Aug 21, 2025 11:29 pm ET1min read
AIM--
The CEO Corner segment, now available on the company's website, highlights the advancements in Ampligen, a first-in-class investigational drug. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for various cancers, viral diseases, and immune disorders, including COVID-19.
Equels emphasized the company's focus on driving Ampligen forward in pancreatic cancer treatment, one of the key areas of interest. He reiterated the company's commitment to its research and development efforts, underscoring the potential of Ampligen in addressing critical global health challenges.
AIM ImmunoTech is an immuno-pharma company dedicated to developing therapeutics for multiple types of cancers, immune disorders, and viral diseases. The company's lead product, Ampligen, has shown promising results in clinical trials, but it is essential to note that these results do not guarantee commercial approval for any indication.
The press release also includes a cautionary statement regarding forward-looking statements, emphasizing the risks and uncertainties associated with the company's future prospects. Investors are advised to review the company's most recent Form 10-K and any subsequent Form 10-Q or Form 8-K filings with the U.S. Securities and Exchange Commission for detailed risk factors.
For more information, please visit aimimmuno.com and connect with the company on X, LinkedIn, and Facebook.
References:
[1] https://www.globenewswire.com/news-release/2025/08/21/3137174/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html
AIM ImmunoTech has published a CEO Corner segment on its website, featuring an update from Chief Executive Officer Thomas Equels. In the segment, Equels discusses the recent scientific progress made with the Company's lead product candidate, Ampligen.
AIM ImmunoTech Inc. (NYSE American: AIM) has published its latest CEO Corner segment, featuring an update from Chief Executive Officer Thomas Equels. In the segment, Equels provides a corporate update and discusses the recent scientific progress made with the company's lead product candidate, Ampligen.The CEO Corner segment, now available on the company's website, highlights the advancements in Ampligen, a first-in-class investigational drug. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for various cancers, viral diseases, and immune disorders, including COVID-19.
Equels emphasized the company's focus on driving Ampligen forward in pancreatic cancer treatment, one of the key areas of interest. He reiterated the company's commitment to its research and development efforts, underscoring the potential of Ampligen in addressing critical global health challenges.
AIM ImmunoTech is an immuno-pharma company dedicated to developing therapeutics for multiple types of cancers, immune disorders, and viral diseases. The company's lead product, Ampligen, has shown promising results in clinical trials, but it is essential to note that these results do not guarantee commercial approval for any indication.
The press release also includes a cautionary statement regarding forward-looking statements, emphasizing the risks and uncertainties associated with the company's future prospects. Investors are advised to review the company's most recent Form 10-K and any subsequent Form 10-Q or Form 8-K filings with the U.S. Securities and Exchange Commission for detailed risk factors.
For more information, please visit aimimmuno.com and connect with the company on X, LinkedIn, and Facebook.
References:
[1] https://www.globenewswire.com/news-release/2025/08/21/3137174/29489/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet